INTERIM REPORT

1 Jan. 2013 till 31 Mar. 2013

This Interim Report is published in Swedish and English. In the event of any difference between the English version and the Swedish original, the Swedish version shall prevail.

The listing on Nasdaq OMX creates possibilities for the future

"After NeuroVive's IPO on NASDAQ OMX Stockholm Small Cap in April, the company has secured prospects for its continued work in its priority business segments relating to CicloMulsion® and NeuroSTAT®."
CEO Mikael Brönnegård

First quarter (1 Jan. 2013 - 31 Mar. 2013)

- Net sales were SEK 0 (0) and other operating income was SEK 704,000 (9,000).
- The loss before tax was SEK -4,739,000 (-2,815,000).
- Earnings per share* were SEK -0.24 (-0.18).
- Diluted earnings per share** were SEK -0.24 (-0.18).

** Profit/loss for the period divided by the average number of shares before dilution at the end of the period.*
***Profit/loss for the period divided by the average number of shares after dilution at the end of the period.*

Business highlights in the first quarter of 2013

- In March, NeuroVive acquired a portfolio of new cyclophilin inhibitors and the associated intellectual property from UK biotech enterprise Biotica Ltd. The purchase of these assets is a significant strategic step because it extends and deepens NeuroVive's proprietary product portfolio of new mitochondrial pharmaceuticals. These new cyclophilin inhibitors are expected to serve as the basis of an upcoming generation of the company's products addressing a broad spectrum of diseases including cardio and neuroprotection.

- On 22 March, NeuroVive reported that over 600 patients had been enrolled in the clinical phase III multi-center trial (CIRCUS), which is evaluating the effects of CicloMulsion® on treating reperfusion injury after stenting coincident with myocardial infarction.

- Nasdaq OMX's Listing Committee approved NeuroVive's application for a listing on Nasdaq OMX Stockholm Small Cap on 22 March.

Post balance sheet events

- On 10 April, NeuroVive was listed on Nasdaq OMX Stockholm Small Cap, with the stock symbol NVP.

- The previously reported arbitration procedure with CicloMulsion AG has been registered with the designated arbitration tribunal.

Comments from our CEO, Mikael Brönnegård

NeuroVive is continuing its intensive efforts to produce pharmaceuticals for patients in a segment with a growing medicinal need. The development of pharmaceuticals that can protect heart and brain cells after acute conditions such as myocardial infarction, stroke and traumatic brain damage is an increasing priority for the pharmaceutical industry, with a growing focus being put on mitochondrial function in health and disease. Cardiovascular disease and acute brain damage not only affect elderly people, but also those of an active and productive age. The current focus of NeuroVive's operations is to complete the current European phase III trial on CicloMulsion®, which has enrolled over 700 patients to date, and to intensify patient enrollment in the recently commenced phased IIa trial on NeuroSTAT® being conducted at Rigshospitalet (the National Hospital) in Copenhagen.

By producing candidate drugs (CDs) for energy regulation and by acquiring new, potent cyclophilin inhibitors from Biotica Ltd already in the preclinical phase, NeuroVive has created promising prospects to maintain strong positioning in mitochondrial medicine. The energy regulation CDs will serve as a foundation for the future treatment of genetic defects that directly affect mitochondrial function resulting in compromised energy production. These new cyclophilin inhibitors are an all-new class of molecules defined as second-generation cyclophilin inhibitors after CsA for treating mitochondrial damage arising after acute heart and brain damage. The benefits of these new cyclophilin inhibitors is their more potent efficacy against mitochondrial dysfunction in preclinical trials, and that they also have very long-term patent protection.

Our collaboration with Sihuan in China is continuing as planned, and we hope to be able to commence a heart trial, complementary to the ongoing European phase III trial on CicloMulsion®. Moreover, the plan in time is to extend the collaboration with Sihuan, and after NeuroVive's and Sihuan's R&D teams met in Jinan, China in mid-March this year, a number of promising partnership projects were identified. Additionally, interest in NeuroVive's products has increased in the Asian region after the agreement with Sihuan became public knowledge.

Our collaboration with Dutch company to-BBB has entered a phase in which various formulations of NVP014 are being trialed in preclinical stroke treatment models. The aim is to obtain the maximum nerve cell protection effect after suffering a stroke. The big challenge when developing CDs for stroke treatment is to ensure the compound penetrates the blood-brain barrier so the desired effect is achieved in the brain. Utilizing to-BBB's technology and optimized formulation, NeuroVive hopes that NVP014 will have the desired effect on brain damage after a stroke.

After NeuroVive's IPO on NASDAQ OMX Stockholm Small Cap in April, the company has secured prospects for its continued work in its priority business segments relating to CicloMulsion® and NeuroSTAT®.

Mikael Brönnegård
CEO, NeuroVive Pharmaceutical AB (publ)

NeuroVive

Operations
NeuroVive conducts research and development into pharmaceuticals that protect the mitochondria. Its drug development technology platform consists of versions of cyclosporine, as well as molecules with similar structures that together constitute a new class of pharmaceuticals called cyclophilin inhibitors. Its product portfolio also includes CDs for cellular energy regulation.

Cyclosporin-A is the active compound in CicloMulsion®/NeuroSTAT® (a CD with different names and application segments) and has been on the market as a pharmaceutical compound for nearly 30 years. There is extensive safety data available on the active compound.

Project overview

Candidate drugs	Indication/purpose	Status
CicloMulsion®	Reperfusion injury in myocardial infarction	Ongoing clinical external phase III trial in the EU Planning phase III trial in China commenced
NeuroSTAT®	Traumatic brain injury	Clinical phase I trial complete Clinical phase II trial approved for commencement Planning of international phase III trial (EU, US and China) commenced
NVP014	Stroke	Preclinical phase
NVP015	Energy regulation in mitochondria	Preclinical phase
Second and third generation of cyclophilin inhibitors	NICAM* NCCIM**	Preclinical evaluation phase

** Non Immunosuppressive Cyclosporin Analogue Molecules (non-immunosuppressive compounds).*
*** Non Cyclosporine Cyclophilin Inhibiting Molecules (non-cyclosporine-based compounds).*

NeuroVive has been granted orphan drug designation for NeuroSTAT® for moderate and severe cranial injury in the US and EU, which means market exclusivity after marketing authorization, even if patents no longer apply. The special designation grants exclusivity for seven (7) years in the US and ten (10) years in the EU, from the date NeuroVive is granted marketing authorization. In itself, the designation does not mean that the CD has demonstrated the efficacy, safety and quality necessary for pharmaceutical registration in the US or Europe. These criteria must be satisfied in the pharmaceutical and clinical phases that regulatory authorities subsequently approve before granting marketing authorization for the pharmaceutical.

Business model
NeuroVive's management is evaluating various types of innovative collaboration with large pharmaceutical companies and/or contract research organization (CRO) partners with the intention of creating a reduced-risk and cost-efficient business model, where NeuroVive can exploit established promotion channels with selected partners to build future business segments such as the marketing and sale of future pharmaceuticals. The business model of strategic alliances with trade partners also enables various forms of direct investment in NeuroVive as a component of funding phase III trials and future straightforward marketing and sales activities. NeuroVive also intends to outlicense pharmaceuticals to large pharmaceutical companies for registration, marketing and sale. The company's revenue can consist of fixed fees from outlicensing, milestone payments on the way to launch, as well as ongoing royalty income based on the sale of outlicensed pharmaceuticals.

NeuroVive is working systematically on accumulating critical mass in the company's current research segments through acquisitions of technologies and projects in the nerve cell and mitochondrial protection research segments and partnerships in technology and product development. Eventually, this acquisition and partnership strategy will promote NeuroVive's prospects of bringing new CDs for traumatic brain damage, and the company's other priority indications, to market. This mitigates the risk of long development cycles for new pharmaceuticals.

Revenue and results of operations

Revenue
The companys other operating income of SEK 704,000 (9,000) for the first quarter, consists mainly of EU subsidies received from Vinnova. The company has not yet started to generate revenues.

Profit/loss
The company's operating loss for the first quarter was SEK -4,863,000 (-2,856,000).

The operating loss was affected by increased external expenses of SEK -4,115,000 (-2,057,000). The main reason for the increased cost is connected to the listing on Nasdaq OMX Stockholm as well as increased consultancy costs due to intensified activities in the development projects. Personnel expenses also increased, SEK -1,333,000 (-762,000), which relates to the increased number of employees compared to the corresponding period last year.

The loss for the period before tax was SEK -4,739,000 (-2,815,000).

Financial position

The equity/assets ratio 88% (88) as of 31 March 2013 and equity was SEK 58,430,000 (63,043,000) compared to the beginning of the year. Cash and cash equivalents were SEK 27,719,000 (37,177,000) as of 31 March 2013, implying a change of SEK -9,458,000 compared to the beginning of the year. Total assets as of 31 March 2013 were SEK 66,400,000 (71,506,000) compared to the beginning of the year.

Cash flow and investments

Consolidated cash flow for the first quarter was SEK -9,458,000 (-2,834,000) where the cash flow decreased with SEK -6,624,000 which mainly relates to investments in immaterial assets, SEK 4,463,000 (-1,419,000), i.e. product development and clinical trials as well as the extraordinary payment in connection with the acquisition of the new cyclophilin inhibitors from Biotica Ltd. Cash flow was also affected by the increased operating loss SEK -4,863,000 (-2,856,000).

Transactions with related parties

Transactions between the company and its subsidiaries, which are related parties to the company, have been eliminated on consolidation, and accordingly, no disclosures are made regarding these transactions. Disclosures regarding transactions between the group and other related parties are stated below.

Apart from remuneration to senior managers including remuneration for consulting services, no purchases or sales between the group and related parties occurred. Transactions with related parties affecting profit/loss for the period are stated below.

Transactions with related parties (SEK 000)	**1 Jan. 2013 31 Mar. 2013**	**1 Jan. 2012 31 Mar. 2012**
Stanbridge bvba (owned by Gregory Batcheller, Executive Chairman)	360	197
Jan Nilsson Konsult (owned by Jan Nilsson, COO, former Board member)	46	25
Ankor Consultants bvba (owned by Arne Ferstad, Board member)	101	42
Total transactions with related bodies	**507**	**264**

Segment information

Financial information reported to the chief operating decision maker (CEO) as the basis for allocating resources and judging the group's profit or loss is not divided into different operating segments. Accordingly, the group consists of a single operating segment.

Human resources

The average number of employees of the group for the period January to March was 6 (3), of which 2 (1) are women.

Parent company

Most of the group's operations are conducted within the parent company. Accordingly, no further specific information regarding the parent company is presented.

Risks and uncertainty factors

A research company such as NeuroVive Pharmaceutical AB (publ) is subject to high operational and financial risks because the projects the company conducts are in different developmental phases, where a number of parameters influence the likelihood of commercial success. Briefly, operations are associated with risks relating to factors including drug development, competition, technological progress, patents, regulatory requirements, capital requirements, currencies and interest rates. In the second quarter 2012, the capital requirement was assured for the company's upcoming development activities. In the current period, there have been no significant changes regarding risks or uncertainty factors. For more detail on these items, refer to the Statutory Administration Report in the Annual Report 2012 and the prospectus published 3rd April 2013, prior to the listing on Nasdaq OMX Stockholm.

Incentive programs/share warrants

The AGM on 10 June 2011 approved an equity-related incentive program for senior managers and/or other employees in the form of an issue of a maximum of 164,000 share warrants, which was fully subscribed. For more information, see note 30 in the Annual Report for 2012.

Audit review

This Interim Report has not been subject to review by the company's auditors.

Upcoming financial statements

- Semi-annual Report 23 August 2013
- Interim Report 3 22 November 2013
- Year-end Report for 2013 21 February 2014

Principles of preparation of the Interim Report

NeuroVive prepares its consolidated accounts in accordance with International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) and interpretation statements from the IFRS Interpretations Committee, as endorsed by the EU for application within the EU. This Interim Report has been prepared in accordance with IAS 34 *Interim Financial Reporting*.

The parent company applies the Swedish Annual Accounts Act and RFR's (the Swedish Financial Reporting Board) recommendation RFR 2 *Accounting for Legal Entities*. Application of RFR 2 implies that, as far as possible, the parent company applies all IFRS endorsed by the EU within the limits of the Swedish Annual Accounts Act and the Swedish Pension Obligations Vesting Act, and considering the relationship between accounting and taxation.

The group and parent company have applied the same accounting principles as described in the Annual Report for 2012 on pages 22-28.

New and revised standards and interpretation statements applicable from 1 January 2013 onwards did not have any effect on the group's or parent company's results of operations or financial position.

Consolidated Statement of Comprehensive Income

(SEK 000)	Note	1 Jan. 2013 31 Mar. 2013	1 Jan. 2012 31 Mar. 2012
Net sales		-	-
Other operating income		704	9
		704	**9**
Operating expenses			
Other external expenses		-4 115	-2 057
Personnel cost		-1 333	-762
Depreciation and write-down of tangible and intangible assets		-38	-26
Other operating expenses		-81	-20
		-5 567	**-2 865**
Operating income		**-4 863**	**-2 856**
Profit/loss from financial items			
Financial income		137	41
Financial costs		-13	-
		124	**41**
Profit/loss before tax		**-4 739**	**-2 815**
Income tax	2	-	-
Profit/loss for the period		**-4 739**	**-2 815**
Other comprehensive income			
Items that may be reclassified to profit or loss			
Translation differences on foreign subsidiaries		126	2
Total comprehensive income for the period		**-4 613**	**-2 813**
Loss for the period attributable to:			
Parent company shareholders		-4 526	-2 619
Non-controlling interests		-213	-196
		-4 739	**-2 815**
Total comprehensive income for the period attributable to:			
Parent company shareholders		-4 438	-2 617
Non-controlling interests		-175	-196
		-4 613	**-2 813**
Earnings per share before and after dilution(SEK) based on average number of shares		-0,24	-0,18

Consolidated Statement of Financial Position

(SEK 000)	Note	31 Mar. 2013	31 Mar. 2012	31 Dec. 2012
ASSETS				
Non-current assets				
Intangible assets	1			
Development costs		32 427	19 224	30 042
Patents		4 867	2 679	2 416
Software		227	307	247
		37 521	**22 210**	**32 705**
Tangible assets				
Equipment		595	157	665
		595	**157**	**665**
Total non-current assets		**38 116**	**22 367**	**33 370**
Current assets				
Other receivables		263	600	734
Prepaid expenses and accrued income		302	135	225
Cash and cash equivalents		27 719	9 961	37 177
		28 284	**10 696**	**38 136**
TOTAL ASSETS		**66 400**	**33 063**	**71 506**

(SEK 000)	Note	31 Mar. 2013	31 Mar. 2012	31 Dec. 2012
EQUITY AND LIABILITIES				
Equity attributable to the shareholders of the parent company				
Share capital		958	747	958
Additional paid in capital		98 049	51 938	98 049
Translation reserve		89	2	27
Retained earnings		-39 433	-22 679	-34 933
Total equity attributable to the shareholders of the parent company		**59 663**	**30 008**	**64 101**
Non-controlling interests		-1 233	-236	-1 058
Total equity		**58 430**	**29 772**	**63 043**
Long-term liabilities				
Deferred tax liabilities		-	-	-
		-	**-**	**-**
Short-term liabilities				
Accounts payable		3 294	1 519	4 724
Other liabilities		1 215	306	1 103
Accrued expenses and deferred income		3 461	1 466	2 636
		7 970	**3 291**	**8 463**
Total liabilities		**7 970**	**3 291**	**8 463**
TOTAL EQUITY AND LIABILITIES		**66 400**	**33 063**	**71 506**

Consolidated Statement of Changes in Equity

Total number of shares at end of period: 19,159,046.

(SEK 000)	**Equity attributable to the shareholders of the parent company**						
	Share capital	Additional paid-in capital	Translation reserve	Retained earnings	Total equity attributable to the shareholders of the parent company	Non-controlling interests	Total equity
Opening balance, 1 January 2013	**958**	**98 049**	**27**	**-34 933**	**64 101**	**-1 058**	**63 043**
Comprehensive profit/loss for the period							
Profit/loss for the period	**-**	**-**	**-**	-4 526	-4 526	-213	-4 739
Other comprehensive income							
Translation differences	-	-	62	26	88	38	126
Other comprehensive profit/loss for the period, net after tax	-	-	62	26	88	38	126
Total comprehensive profit/loss	**-**	**-**	**62**	**-4 500**	**-4 438**	**-175**	**-4 613**
Transactions with shareholders							
New share issue	-	-	-	-	-	-	-
Total transactions with shareholders	-	-	-	-	-	-	-
Closing balance, 31 March 2013	**958**	**98 049**	**89**	**-39 433**	**59 663**	**1 233**	**58 430**
Opening balance, 1 January 2012	**747**	**51 938**	**-**	**-20 060**	**32 625**	**-40**	**32 585**
Comprehensive profit/loss for the period							
Profit/loss for the period	**-**	**-**	**-**	-2 619	-2 619	-196	-2 815
Other comprehensive income							
Translation differences	-	-	2	-	2	-	2
Other comprehensive profit/loss for the period, net after tax	-	-	2	-	2	-	2
Total comprehensive profit/loss	**-**	**-**	**2**	**-2 619**	**-2 617**	**-196**	**-2 813**
Transactions with shareholders							
New share issue	-	-	-	-	-	-	-
Total transactions with shareholders	-	-	-	-	-	-	-
Closing balance, 31 March 2012	**747**	**51 938**	**2**	**-22 679**	**30 008**	**-236**	**29 772**
Opening balance, 1 April 2012	**747**	**51 938**	**2**	**-22 679**	**30 008**	**-236**	**29 772**
Comprehensive profit/loss for the period							
Profit/loss for the period	**-**	**-**	**-**	-12 254	-12 254	-834	-13 088
Other comprehensive income							
Translation differences	-	-	25	-	25	12	37
Other comprehensive profit/loss for the period, net after tax	-	-	25	-	25	12	37
Total comprehensive profit/loss	**-**	**-**	**25**	**-12 254**	**-12 229**	**-822**	**-13 051**
Transactions with shareholders							
New share issue	211	46 111	-	-	46 322	-	46 322
Total transactions with shareholders	211	46 111	-	-	46 322	-	46 322
Closing balance, 31 December 2012	**958**	**98 049**	**27**	**-34 933**	**64 101**	**-1 058**	**63 043**

Consolidated Statement of Cash Flows

(SEK 000)	1 Jan. 31 Mar.	1 Jan. 2012 31 Mar. 2012
Cash flow from operating activities		
Operating income	-4 863	-2 856
Adjustments for non-cash items:		
Depreciation	38	26
Currency differences on intercompany items	98	-
Interest received	148	41
Interest paid	-13	-
Net cash from operating activities before changes in working capital	**-4 592**	**-2 789**
Changes in working capital		
Increase/decrease of other current assets	383	-234
Increase/decrease of other short-term liabilities	-786	1634
Changes in working capital	**-403**	**1 400**
Cash flow from operating activities	**-4 995**	**-1 389**
Investing activities		
Acquisition of tangible assets	-	-26
Acquisition of intangible assets	-4 463	-1 419
Cash flow from investing activities	**-4 463**	**-1 445**
Financing activities		
New share issue	-	-
Cash flow from financing activities	**-**	**-**
Cash flow for the period	-9 458	-2 834
Cash and cash equivalents at the beginning of the period	37 177	12 795
Cash and cash equivalents at end of period	**27 719**	**9 961**

Parent Company Income Statement

(SEK 000)	Note	1 Jan. 2013 31 Mar. 2013	1 Jan. 2012 31 Mar. 2012
Net sales		-	-
Other operating income		704	9
		704	**9**
Operating expenses			
Other external expenses		-3 442	-1 403
Personnel cost		-1 333	-762
Depreciation and write-down of tangible and intangible assets		-38	-26
Other operating expenses		-81	-20
		-4 894	**-2 211**
Operating income		**-4 190**	**-2 202**
Profit/loss from financial items			
Interest income and other similar profit items		162	41
Interest expenses and other similar loss items		-2	-1
		160	**40**
Profit/loss before tax		**-4 030**	**-2 162**
Income tax	2	-	-
Profit/loss for the period		**-4 030**	**-2 162**

Statement of Comprehensive Income, Parent Company

(SEK 000)	Note	1 Jan. 2013 31 Mar. 2013	1 Jan. 2012 31 Mar. 2012
Profit/loss for the period		-4 030	-2 162
Other comprehensive income		-	-
Total comprehensive profit/loss for the period		**-4 030**	**-2 162**

Parent Company Balance Sheet

(SEK 000)	Note	31 Mar. 2013	31 Mar. 2012	31 Dec. 2012
ASSETS				
Non-current assets				
Intangible assets	1			
Development costs		32 427	19 224	30 042
Patents		4 867	2 679	2 416
Software		227	307	247
		37 521	**22 210**	**32 705**
Tangible assets				
Equipment		596	157	665
		596	**157**	**665**
Financial assets				
Shares in subsidiaries	3	6	6	6
		6	**6**	**6**
Total non-current assets		**38 123**	**22 373**	**33 376**
Current assets				
Short term receivables				
Receivables from group companies		3 133	556	2 716
Other receivables		260	596	732
Prepaid expenses and accrued income		282	136	225
		3 675	**1 288**	**3 673**
Cash and bank balances		27 717	9 961	37 177
Total current assets		**31 392**	**11 249**	**40 850**
TOTAL ASSETS		**69 515**	**33 622**	**74 226**

(SEK 000)	Note	31 Mar. 2013	31 Mar. 2012	31 Dec. 2012
EQUITY AND LIABILITIES				
Equity				
Restricted equity				
Share capital		958	747	958
Statutory reserve		1 856	1 856	1 856
		2 814	2 603	2 814
Unrestricted equity				
Share premium reserve		-	-	46 111
Retained earnings		63 761	30 122	30 122
Profit/loss for the period		-4 030	-2 162	-12 471
		59 731	27 960	63 762
Total equity		**62 545**	**30 563**	**66 576**
Provision				
Deferred tax liabilities		-	-	-
		-	**-**	**-**
Short-term liabilities				
Accounts payable		3 294	1 519	4 724
Liabilities to group companies		6	6	6
Other liabilities		209	68	284
Accrued expenses and deferred income		3 461	1 466	2 636
		6 970	**3 059**	**7 650**
TOTAL EQUITY AND LIABILITIES		**69 515**	**33 622**	**74 226**

Note 1—Intangible assets

(SEK 000)	Development costs	Patents*	Software	Total
ACCUMULATED COST				
Opening balance 1 Jan. 2013	**30 042**	**4 724**	**400**	**35 166**
Additions	2 385	2 661	-	5 046
Closing balance 31 Mar. 2013	**32 427**	**7 385**	**400**	**40 212**
ACCUMULATED DEPRECIATION				
Opening balance 1 Jan. 2013	**-**	**-2 308**	**-153**	**-2 461**
Depreciation for the period	-	-210	-20	-230
Closing balance 31 Mar. 2013	**-**	**-2 518**	**-173**	**-2 691**
Residual value 31 Mar. 2013	**32 427**	**4 867**	**227**	**37 521**

(SEK 000)	Development costs	Patents*	Software	Total
ACCUMULATED COST				
Opening balance 1 Jan. 2012	**17 840**	**4 083**	**400**	**22 323**
Additions	12 434	641	-	13 075
Government grants	-232	-	-	-232
Closing balance 31 Dec. 2012	**30 042**	**4 724**	**400**	**35 166**
ACCUMULATED DEPRECIATION				
Opening balance 1 Jan. 2012	**-**	**-1 452**	**-73**	**-1 525**
Depreciation for the period	-	-856	-80	-936
Closing balance 31 Dec. 2012	**-**	**-2 308**	**-153**	**-2 461**
Residual value 31 Dec. 2012	**30 042**	**2 416**	**247**	**32 705**

* Amortization of patents is recognized as a portion of historical cost of capitalized expenditure from product development because patents are used in development work.

Of total capitalized expenditure for product development, 63% is for NeuroSTAT, 35% is for CicloMulsion, 2% is for NVP014.

Note 2—Tax
The group's total loss carry-forwards amount to SEK 53,870,000 as of 31 March 2013 (49,559,000 31 December 2012). The parent company's total loss carry-forwards amount to SEK 49,942,000 as of 31 March 2013 (46,127,000 31 December 2012). Because the company is loss making, management cannot judge when deductible loss carry-forwards will be utilized.

Note 3—Shares and participations in group companies
These shares are the holding of 70% in Hong Kong-registered subsidiary Neuroive Pharmaceutical Asia Ltd., which was incorporated in December 2011.

This Interim Report gives a true and fair view of the parent company's and group's operations, financial position and results of operations, and states the significant risks and uncertainty factors facing the parent company and group companies.

Greg Batcheller
Chairman of the Board

Arne Ferstad
Board member

Boel Flodgren
Board member

Marcus Keep
Board member

Helena Levander
Board member

Anna Malm Bernsten
Board member

Helmut von Moltke
Board member

Mikael Brönnegård
Chief Executive Officer

Lund, Sweden, 24 May 2013

This Interim Report is published in Swedish and English. In the event of any difference between the English version and the Swedish original, the Swedish version shall prevail.

<u>For more information, please contact:</u>

Mikael Brönnegård, CEO

Telephone: +46 (0)46 275 6220 (switchboard)
Email: mikael.bronnegard@neurovive.se
Website: www.neurovive.se
Address: Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden